KEITH M GOTTESDIENER

Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease RAHWAY, NJ NPI 1821150376

General Payments — all program years on this page

$2,389,037.07

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 103
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $115,550.00 across 5 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $115,550.005

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $115,550.005

By program year

Program yearAmountRecords
2018 $279,284.8215
2019 $331,343.7919
2020 $331,189.2317
2021 $356,722.2216
2022 $335,000.0015
2023 $639,947.0116
2024 $115,550.005

Records — PY2024 (5)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1137560438 Takeda Pharmaceuticals U.S.A., Inc. $25,000.00 01/03/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137560444 Takeda Pharmaceuticals U.S.A., Inc. $25,000.00 01/17/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137560446 Takeda Pharmaceuticals U.S.A., Inc. $25,000.00 02/21/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137560450 Takeda Pharmaceuticals U.S.A., Inc. $25,000.00 04/03/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137560454 Takeda Pharmaceuticals U.S.A., Inc. $15,550.00 10/21/2024 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.